Journal of the Formosan Medical Association
Volume 108, Issue 11 , Pages 827-829 , November 2009

HIV-1 Vaccine—Many Miles to Go Before We Sleep

  • Kuan-Teh Jeang

      Affiliations

    • National Institutes of Health, Bethesda, Maryland, USA
    • Corresponding Author InformationCorrespondence to: Dr Kuan-Teh Jeang, Molecular Virology Section, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health Building 4, Room 306, 9000 Rockville Pike, Bethesda, Maryland 20892-0460, USA
    • ,
  • Li-Min Huang

      Affiliations

    • Department of Pediatrics, National Taiwan University, Taipei, Taiwan

References 

  1. Huang LM , Jeang KT . HIV-1 at age 25: some thoughts for Taiwan and China . J Formos Med Assoc . 2008;107:907–908
  2. Shao Y . AIDS epidemic at age 25 and control efforts in China . Retrovirology . 2006;3:87
  3. Chen J , Hong K , Jia M , et al.   Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B′/C Recombinant (CRF07_BC) . Retrovirology . 2007;4:62
  4. Wainberg MA , Jeang KT . 25 years of HIV-1 research— progress and perspectives . BMC Med . 2008;6:31
  5. Flynn NM , Forthal DN , Harro CD , et al.   Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection . J Infect Dis . 2005;191:654–665
  6. Buchbinder SP , Mehrotra DV , Duerr A , et al.   Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial . Lancet . 2008;372:1881–1893
  7. Pitisuttithum P , Gilbert P , Gurwith M , et al.   Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand . J Infect Dis . 2006;194:1661–1671
  8. Iaccino E , Schiavone M , Fiume G , et al.   The aftermath of the Merck's HIV vaccine trial . Retrovirology . 2008;5:56
  9. Rerks-Ngarm S , Pitisuttithum P , Nitayaphan S , et al.   Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand . N Engl J Med . 2009 Oct 20; [Epub ahead of print]
  10. Brittain E , Lin D . A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials . Stat Med . 2005;24:1–10
  11. Wright CC , Sim J . Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis . J Clin Epidemiol . 2003;56:833–842
  12. Sheiner LB , Rubin DB . Intention-to-treat analysis and the goals of clinical trials . Clin Pharmacol Ther . 1995;7:6–15
  13. Heritier SR , Gebski VJ , Keech AC . Inclusion of patients in clinical trial analysis: the intention-to-treat principle . Med J Aust . 2003;179:438–440
  14. Porta N , Bonet C , Cobo E . Discordance between reported intention-to-treat and per protocol analyses . J Clin Epidemiol . 2007;60:663–669
  15. Berkhout B , Paxton WA . HIV vaccine: it may take two to tango, but no party time yet . Retrovirology . 2009;6:88
  16. Lama J , Planelles V . Host factors influencing susceptibility to HIV infection and AIDS progression . Retrovirology . 2007;4:52
  17. Strebel K , Luban J , Jeang KT . Human cellular restriction factors that target HIV-1 replication . BMC Med . 2009;7:48

PII: S0929-6646(09)60412-5

doi: 10.1016/S0929-6646(09)60412-5

Journal of the Formosan Medical Association
Volume 108, Issue 11 , Pages 827-829 , November 2009

Article Tools